TABLE 1

Anthropometric and metabolic characteristics of participants not treated with either hypoglycemic or lipid-lowering drugs at inclusion in the study, with data stratified according to GCKR rs1260326 genotype

CCCTTTPadditiveΔ% (95% CI)
n4,3631,3832,125855
Sex ratio (male/female)2,135/2,228666/7171,044/1,081425/430
Age (years)46.5 ± 9.7946.3 ± 9.8346.7 ± 9.846.5 ± 9.69
BMI (kg/m2)24.5 ± 3.7724.4 ± 3.6424.6 ± 3.9424.5 ± 3.530.80.09 (−0.50 to 0.68)
Waist-to-hip ratio0.85 ± 0.090.85 ± 0.090.85 ± 0.090.85 ± 0.090.2−0.16 (−0.42 to 0.09)
Fasting glucose (mmol/l)5.31 ± 0.685.37 ± 0.745.30 ± 0.645.24 ± 0.689 × 10−9−1.27 (−1.70 to −0.84)
Fasting insulin (pmol/l)46.0 ± 29.0746.8 ± 27.4946.8 ± 31.4742.9 ± 24.865 × 10−5−3.90 (−5.72 to −2.04)
HOMA-B89.7 ± 61.2787.6 ± 50.8990.7 ± 57.2990.9 ± 82.580.90.11 (−2.19 to 2.46)
HOMA-IR1.82 ± 1.271.88 ± 1.331.84 ± 1.311.68 ± 1.074 × 10−6−5.45 (−7.66 to −3.18)
Total cholesterol (mmol/l)5.74 ± 1.035.75 ± 1.045.73 ± 1.025.74 ± 1.030.5−0.24 (−0.94 to 0.46)
LDL cholesterol (mmol/l)3.58 ± 0.923.61 ± 0.953.56 ± 0.913.57 ± 0.940.2−0.75 (−1.82 to 0.33)
HDL cholesterol (mmol/l)1.64 ± 0.431.64 ± 0.431.64 ± 0.431.63 ± 0.410.80.14 (−0.86 to 1.14)
TG (mmol/l)1.16 ± 1.081.12 ± 1.21.17 ± 1.081.21 ± 0.835 × 10−43.69 (1.61 to 5.82)
  • Data are means ± SD or n unless otherwise indicated. The P values indicated are nominal P-values. Δ% is the percentage of variation of the trait per supplementary minor T-allele. P values and Δ% are from linear regression models adjusted for age, sex, and BMI. HOMA-B, homeostasis model assessment of β-cell function; HOMA-IR, homeostasis model assessment of insulin resistance; TG, triglycerides.